speb/financial-data huggingface dataset:
XRAY cash_flow (quarterly, 2024-09-30) — Short Term Debt Issuance: 56000000.00
XRAY income_statement (annual, 2024-12-31) — +Operating Expense: 1770000000.00
XRAY income_statement (annual, 2024-12-31) — +Total Revenue: 3793000000.00
XRAY balance_sheet (annual, 2024-12-31) — Accounts Payable: 241000000.00
XRAY balance_sheet (annual, 2024-12-31) — Accounts Receivable: 556000000.00
XRAY balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -1341000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -1341000000.00
XRAY balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 6640000000.00
XRAY balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -14000000.00
XRAY cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 216000000.00
XRAY cash_flow (annual, 2024-12-31) — Amortization Of Intangibles: 216000000.00
XRAY cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 1014000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 504000000.00
XRAY income_statement (annual, 2024-12-31) — Basic Average Shares: 203200000.00
XRAY income_statement (annual, 2024-12-31) — Basic EPS: -4.48
XRAY cash_flow (annual, 2024-12-31) — Beginning Cash Position: 334000000.00
XRAY balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 571000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 571000000.00
XRAY cash_flow (annual, 2024-12-31) — Capital Expenditure: -180000000.00
XRAY cash_flow (annual, 2024-12-31) — Capital Expenditure Reported: -180000000.00
XRAY balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 137000000.00
XRAY balance_sheet (annual, 2024-12-31) — Capital Stock: 3000000.00
XRAY balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 272000000.00
XRAY balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 272000000.00
XRAY cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -126000000.00
XRAY cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -302000000.00
XRAY cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -197000000.00
XRAY cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 461000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Account Payable: -30000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -39000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Inventory: 17000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -5000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -28000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 38000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Payable: -30000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -69000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 38000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Receivables: 104000000.00
XRAY cash_flow (annual, 2024-12-31) — Change In Working Capital: 95000000.00
XRAY cash_flow (annual, 2024-12-31) — Changes In Cash: -38000000.00
XRAY balance_sheet (annual, 2024-12-31) — Commercial Paper: 410000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Commercial Paper: 410000000.00
XRAY balance_sheet (annual, 2024-12-31) — Common Stock: 3000000.00
XRAY balance_sheet (annual, 2024-12-31) — Common Stock Equity: 1942000000.00
XRAY cash_flow (annual, 2024-12-31) — Common Stock Payments: -250000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Common Stock Payments: 0.00
XRAY balance_sheet (annual, 2024-12-31) — Construction In Progress: 87000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 87000000.00
XRAY income_statement (annual, 2024-12-31) — Cost Of Revenue: 1835000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 330000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Assets: 1746000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 46000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 46000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Debt: 549000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 595000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 95000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Current Deferred Liabilities: 95000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 95000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Current Deferred Revenue: 95000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Liabilities: 1589000000.00
XRAY balance_sheet (annual, 2024-12-31) — Current Provisions: 116000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Current Provisions: 116000000.00
XRAY cash_flow (annual, 2024-12-31) — Deferred Income Tax: -136000000.00
XRAY cash_flow (annual, 2024-12-31) — Deferred Tax: -136000000.00
XRAY cash_flow (annual, 2024-12-31) — Depreciation: 133000000.00
XRAY cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 349000000.00
XRAY cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 349000000.00
XRAY income_statement (annual, 2024-12-31) — Diluted Average Shares: 203200000.00
XRAY income_statement (annual, 2024-12-31) — Diluted EPS: -4.48
XRAY income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -910000000.00
XRAY income_statement (annual, 2024-12-31) — EBIT: -867000000.00
XRAY income_statement (annual, 2024-12-31) — EBITDA: -518000000.00
XRAY cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: 0.00
XRAY cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -24000000.00
XRAY cash_flow (annual, 2024-12-31) — End Cash Position: 272000000.00
XRAY cash_flow (annual, 2024-12-31) — Financing Cash Flow: -302000000.00
XRAY balance_sheet (annual, 2024-12-31) — Finished Goods: 320000000.00
XRAY cash_flow (annual, 2024-12-31) — Free Cash Flow: 281000000.00
XRAY cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 19000000.00
XRAY income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 21000000.00
XRAY balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -730000000.00
XRAY balance_sheet (annual, 2024-12-31) — Goodwill: 1597000000.00
XRAY balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 2804000000.00
XRAY balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 570000000.00
XRAY balance_sheet (annual, 2024-12-31) — Gross PPE: 2243000000.00
XRAY income_statement (annual, 2024-12-31) — Gross Profit: 1958000000.00
XRAY income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 1014000000.00
XRAY income_statement (quarterly, 2024-12-31) — Impairment Of Capital Assets: 504000000.00
XRAY cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 74000000.00
XRAY balance_sheet (annual, 2024-12-31) — Income Tax Payable: 45000000.00
XRAY income_statement (annual, 2024-12-31) — Interest Expense: 69000000.00
XRAY income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 69000000.00
XRAY cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 91000000.00
XRAY balance_sheet (annual, 2024-12-31) — Interest Payable: 8000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Interest Payable: 8000000.00
XRAY balance_sheet (annual, 2024-12-31) — Inventory: 564000000.00
XRAY balance_sheet (annual, 2024-12-31) — Invested Capital: 4077000000.00
XRAY cash_flow (annual, 2024-12-31) — Investing Cash Flow: -197000000.00
XRAY cash_flow (annual, 2024-12-31) — Issuance Of Debt: 178000000.00
XRAY balance_sheet (annual, 2024-12-31) — Land And Improvements: 46000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 46000000.00
XRAY balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 91000000.00
XRAY balance_sheet (annual, 2024-12-31) — Long Term Debt: 1586000000.00
XRAY balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1677000000.00
XRAY cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 1000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 1000000.00
XRAY cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -88000000.00
XRAY balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 1403000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 1403000000.00
XRAY balance_sheet (annual, 2024-12-31) — Minority Interest: 1000000.00
XRAY income_statement (annual, 2024-12-31) — Minority Interests: 0.00
XRAY cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
XRAY cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -250000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
XRAY balance_sheet (annual, 2024-12-31) — Net Debt: 1863000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -910000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -910000000.00
XRAY income_statement (annual, 2024-12-31) — Net Interest Income: -69000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -11000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 90000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -87000000.00
XRAY income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -69000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -16000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -6000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Net Other Investing Changes: -7000000.00
XRAY balance_sheet (annual, 2024-12-31) — Net PPE: 902000000.00
XRAY cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 177000000.00
XRAY balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -862000000.00
XRAY balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 129000000.00
XRAY balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 129000000.00
XRAY income_statement (annual, 2024-12-31) — Normalized EBITDA: 528000000.00
XRAY income_statement (annual, 2024-12-31) — Normalized Income: 106712000.00
XRAY cash_flow (annual, 2024-12-31) — Operating Cash Flow: 461000000.00
XRAY cash_flow (annual, 2024-12-31) — Operating Gains Losses: 19000000.00
XRAY income_statement (annual, 2024-12-31) — Operating Income: 188000000.00
XRAY income_statement (annual, 2024-12-31) — Operating Revenue: 3793000000.00
XRAY balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 198800000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Current Assets: 153000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 139000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Other Current Borrowings: 139000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 12000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 12000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -730000000.00
XRAY income_statement (annual, 2024-12-31) — Other Income Expense: -1055000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 1207000000.00
XRAY cash_flow (annual, 2024-12-31) — Other Non Cash Items: -9000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 301000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 415000000.00
XRAY income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -9000000.00
XRAY income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: -8000000.00
XRAY balance_sheet (annual, 2024-12-31) — Other Properties: 136000000.00
XRAY balance_sheet (annual, 2024-12-31) — Payables: 286000000.00
XRAY balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 616000000.00
XRAY balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 155000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 155000000.00
XRAY balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
XRAY balance_sheet (annual, 2024-12-31) — Prepaid Assets: 151000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 151000000.00
XRAY income_statement (annual, 2024-12-31) — Pretax Income: -936000000.00
XRAY balance_sheet (annual, 2024-12-31) — Properties: 0.00
XRAY balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
XRAY cash_flow (annual, 2024-12-31) — Purchase Of Investment: -12000000.00
XRAY balance_sheet (annual, 2024-12-31) — Raw Materials: 172000000.00
XRAY balance_sheet (annual, 2024-12-31) — Receivables: 606000000.00
XRAY income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 1835000000.00
XRAY income_statement (annual, 2024-12-31) — Reconciled Depreciation: 349000000.00
XRAY cash_flow (annual, 2024-12-31) — Repayment Of Debt: -88000000.00
XRAY cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -250000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
XRAY income_statement (annual, 2024-12-31) — Research And Development: 165000000.00
XRAY income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 53000000.00
XRAY balance_sheet (annual, 2024-12-31) — Retained Earnings: -835000000.00
XRAY cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
XRAY cash_flow (annual, 2024-12-31) — Sale Of Investment: 1000000.00
XRAY cash_flow (quarterly, 2024-12-31) — Sale Of Investment: 1000000.00
XRAY income_statement (annual, 2024-12-31) — Selling General And Administration: 1605000000.00
XRAY balance_sheet (annual, 2024-12-31) — Share Issued: 264500000.00
XRAY cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 177000000.00
XRAY cash_flow (annual, 2024-12-31) — Short Term Debt Payments: 0.00
XRAY income_statement (annual, 2024-12-31) — Special Income Charges: -1067000000.00
XRAY cash_flow (annual, 2024-12-31) — Stock Based Compensation: 39000000.00
XRAY balance_sheet (annual, 2024-12-31) — Stockholders Equity: 1942000000.00
XRAY balance_sheet (annual, 2024-12-31) — Tangible Book Value: -862000000.00
XRAY income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -29288000.00
XRAY income_statement (annual, 2024-12-31) — Tax Provision: -26000000.00
XRAY income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.03
XRAY balance_sheet (annual, 2024-12-31) — Taxes Receivable: 50000000.00
XRAY balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 50000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Assets: 5753000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Capitalization: 3528000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Debt: 2272000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 1943000000.00
XRAY income_statement (annual, 2024-12-31) — Total Expenses: 3605000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 3810000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 4007000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2221000000.00
XRAY income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -879000000.00
XRAY balance_sheet (annual, 2024-12-31) — Total Tax Payable: 45000000.00
XRAY income_statement (annual, 2024-12-31) — Total Unusual Items: -1046000000.00
XRAY income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1046000000.00
XRAY balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 65700000.00
XRAY balance_sheet (annual, 2024-12-31) — Treasury Stock: 3136000000.00
XRAY balance_sheet (annual, 2024-12-31) — Work In Process: 72000000.00
XRAY balance_sheet (annual, 2024-12-31) — Working Capital: 157000000.00
XRAY income_statement (quarterly, 2025-03-31) — +Operating Expense: 396000000.00
XRAY income_statement (quarterly, 2025-03-31) — +Total Revenue: 879000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 276000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 604000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 6631000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -9000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 45000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 45000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 0.00
XRAY income_statement (quarterly, 2025-03-31) — Basic Average Shares: 199100000.00
XRAY income_statement (quarterly, 2025-03-31) — Basic EPS: 0.10
XRAY cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 272000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -19000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Capital Expenditure Reported: -19000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 88000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Capital Stock: 3000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 398000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 398000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -32000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 123000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -17000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 7000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 14000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -44000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Inventory: -26000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 4000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -15000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -12000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Payable: 14000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -30000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -1000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Receivables: -31000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -111000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Changes In Cash: 113000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Common Stock: 3000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -32000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 2010000000.00
XRAY income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 413000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 738000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Assets: 1978000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Debt: 742000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 742000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1793000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Current Notes Payable: 742000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: 1000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Deferred Tax: 1000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Depreciation: 34000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 79000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 79000000.00
XRAY income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 199800000.00
XRAY income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.10
XRAY income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 20000000.00
XRAY income_statement (quarterly, 2025-03-31) — EBIT: 63000000.00
XRAY income_statement (quarterly, 2025-03-31) — EBITDA: 142000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 13000000.00
XRAY cash_flow (quarterly, 2025-03-31) — End Cash Position: 398000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 123000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Finished Goods: 348000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -12000000.00
XRAY income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 2000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -659000000.00
XRAY income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 360000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Goodwill: 1632000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 2844000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 613000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Gross PPE: 924000000.00
XRAY income_statement (quarterly, 2025-03-31) — Gross Profit: 466000000.00
XRAY income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: 0.00
XRAY balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 37000000.00
XRAY income_statement (quarterly, 2025-03-31) — Interest Expense: 19000000.00
XRAY income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 19000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 13000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Inventory: 612000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Invested Capital: 4345000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -17000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 435000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 88000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1593000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1681000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -2000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
XRAY income_statement (quarterly, 2025-03-31) — Minority Interests: 1000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Net Debt: 1937000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income: 20000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 20000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 19000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 20000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 20000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 19000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 19000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Interest Income: -19000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 161000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -2000000.00
XRAY income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -19000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -6000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 2000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Net PPE: 924000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: 1000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: 163000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -834000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 134000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 134000000.00
XRAY income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 149000000.00
XRAY income_statement (quarterly, 2025-03-31) — Normalized Income: 25530000.00
XRAY cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 7000000.00
XRAY income_statement (quarterly, 2025-03-31) — Operating Income: 70000000.00
XRAY income_statement (quarterly, 2025-03-31) — Operating Revenue: 879000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 199300000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 364000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -659000000.00
XRAY income_statement (quarterly, 2025-03-31) — Other Gand A: 358000000.00
XRAY income_statement (quarterly, 2025-03-31) — Other Income Expense: -7000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 1212000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 9000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 304000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 432000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Other Properties: 924000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Payables: 313000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 1051000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
XRAY income_statement (quarterly, 2025-03-31) — Pretax Income: 44000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
XRAY balance_sheet (quarterly, 2025-03-31) — Raw Materials: 184000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Receivables: 604000000.00
XRAY income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 413000000.00
XRAY income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 79000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -274000000.00
XRAY income_statement (quarterly, 2025-03-31) — Research And Development: 36000000.00
XRAY income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 9000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -848000000.00
XRAY income_statement (quarterly, 2025-03-31) — Salaries And Wages: 2000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 1000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 1000000.00
XRAY income_statement (quarterly, 2025-03-31) — Selling General And Administration: 360000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Share Issued: 264500000.00
XRAY cash_flow (quarterly, 2025-03-31) — Short Term Debt Issuance: 435000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Short Term Debt Payments: -272000000.00
XRAY income_statement (quarterly, 2025-03-31) — Special Income Charges: -9000000.00
XRAY cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 10000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 2010000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -834000000.00
XRAY income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1470000.00
XRAY income_statement (quarterly, 2025-03-31) — Tax Provision: 25000000.00
XRAY income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
XRAY balance_sheet (quarterly, 2025-03-31) — Total Assets: 6050000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 3603000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Debt: 2423000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 2010000000.00
XRAY income_statement (quarterly, 2025-03-31) — Total Expenses: 809000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 4040000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 4072000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2247000000.00
XRAY income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 63000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 37000000.00
XRAY income_statement (quarterly, 2025-03-31) — Total Unusual Items: -7000000.00
XRAY income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -7000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 65200000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 3117000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Work In Process: 80000000.00
XRAY balance_sheet (quarterly, 2025-03-31) — Working Capital: 185000000.00
XRAY income_statement (quarterly, 2025-06-30) — +Operating Expense: 380000000.00
XRAY income_statement (quarterly, 2025-06-30) — +Total Revenue: 936000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 268000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 646000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 6638000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -11000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 54000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 54000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: 235000000.00
XRAY income_statement (quarterly, 2025-06-30) — Basic Average Shares: 199300000.00
XRAY income_statement (quarterly, 2025-06-30) — Basic EPS: -0.22
XRAY cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 398000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -32000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -32000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 92000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Capital Stock: 3000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 359000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 359000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -32000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -68000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -34000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 48000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -24000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 9000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Inventory: -21000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -3000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -58000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -43000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Payable: -24000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -15000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 27000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Receivables: 0.00
XRAY cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -113000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Changes In Cash: -54000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Common Stock: 3000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -32000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 1960000000.00
XRAY income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 446000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 672000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Current Assets: 1966000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Current Debt: 184000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 184000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 1166000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -137000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Deferred Tax: -137000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Depreciation: 34000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 88000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 88000000.00
XRAY income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 199300000.00
XRAY income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.22
XRAY income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -45000000.00
XRAY income_statement (quarterly, 2025-06-30) — EBIT: -129000000.00
XRAY income_statement (quarterly, 2025-06-30) — EBITDA: -41000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 15000000.00
XRAY cash_flow (quarterly, 2025-06-30) — End Cash Position: 359000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -68000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Finished Goods: 389000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 16000000.00
XRAY income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -1000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -641000000.00
XRAY income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 343000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Goodwill: 1528000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 2661000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 657000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Gross PPE: 979000000.00
XRAY income_statement (quarterly, 2025-06-30) — Gross Profit: 490000000.00
XRAY income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 235000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 42000000.00
XRAY income_statement (quarterly, 2025-06-30) — Interest Expense: 24000000.00
XRAY income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 24000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Inventory: 675000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Invested Capital: 4362000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -34000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 550000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 92000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 2218000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 2310000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -435000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Minority Interest: 1000000.00
XRAY income_statement (quarterly, 2025-06-30) — Minority Interests: -1000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Net Debt: 2043000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income: -45000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -45000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -44000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -45000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -45000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -44000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -44000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Interest Income: -24000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -1000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -26000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: 550000000.00
XRAY income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -24000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -10000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Net PPE: 979000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: 0.00
XRAY cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: -576000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -701000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 109000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 109000000.00
XRAY income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 199000000.00
XRAY income_statement (quarterly, 2025-06-30) — Normalized Income: 144600000.00
XRAY cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 48000000.00
XRAY income_statement (quarterly, 2025-06-30) — Operating Income: 110000000.00
XRAY income_statement (quarterly, 2025-06-30) — Operating Revenue: 936000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 199300000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 286000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -641000000.00
XRAY income_statement (quarterly, 2025-06-30) — Other Gand A: 342000000.00
XRAY income_statement (quarterly, 2025-06-30) — Other Income Expense: -238000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 1133000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 10000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 463000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 523000000.00
XRAY income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 2000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Other Properties: 979000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Payables: 310000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 982000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
XRAY income_statement (quarterly, 2025-06-30) — Pretax Income: -153000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -2000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Raw Materials: 198000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Receivables: 646000000.00
XRAY income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 446000000.00
XRAY income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 88000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -163000000.00
XRAY income_statement (quarterly, 2025-06-30) — Research And Development: 37000000.00
XRAY income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 4000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -925000000.00
XRAY income_statement (quarterly, 2025-06-30) — Salaries And Wages: 1000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 0.00
XRAY cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 0.00
XRAY income_statement (quarterly, 2025-06-30) — Selling General And Administration: 343000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Share Issued: 264500000.00
XRAY income_statement (quarterly, 2025-06-30) — Special Income Charges: -239000000.00
XRAY cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 9000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 1960000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -701000000.00
XRAY income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -50400000.00
XRAY income_statement (quarterly, 2025-06-30) — Tax Provision: -109000000.00
XRAY income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
XRAY balance_sheet (quarterly, 2025-06-30) — Total Assets: 6069000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 4178000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Debt: 2494000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 1961000000.00
XRAY income_statement (quarterly, 2025-06-30) — Total Expenses: 826000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 4108000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 4103000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2942000000.00
XRAY income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -128000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 42000000.00
XRAY income_statement (quarterly, 2025-06-30) — Total Unusual Items: -240000000.00
XRAY income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -240000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 65200000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 3115000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Work In Process: 88000000.00
XRAY balance_sheet (quarterly, 2025-06-30) — Working Capital: 800000000.00
XRAY income_statement (quarterly, 2025-09-30) — +Operating Expense: 395000000.00
XRAY income_statement (quarterly, 2025-09-30) — +Total Revenue: 904000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 268000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 654000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 6638000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -12000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 56000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 56000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 262000000.00
XRAY income_statement (quarterly, 2025-09-30) — Basic Average Shares: 199500000.00
XRAY income_statement (quarterly, 2025-09-30) — Basic EPS: -2.14
XRAY cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 359000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -39000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -39000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 85000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Capital Stock: 3000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 363000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 363000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -32000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -36000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -36000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 79000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 1000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: -31000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Inventory: -14000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: -1000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: 69000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 10000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Payable: 1000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -30000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -36000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Receivables: -25000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -27000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Changes In Cash: 7000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Common Stock: 3000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: -32000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 1478000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Common Stock Payments: 0.00
XRAY income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 463000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 712000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Current Assets: 2072000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Current Debt: 378000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 378000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1405000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 180000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Deferred Tax: 180000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Depreciation: 36000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 92000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 92000000.00
XRAY income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 199500000.00
XRAY income_statement (quarterly, 2025-09-30) — Diluted EPS: -2.14
XRAY income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -427000000.00
XRAY income_statement (quarterly, 2025-09-30) — EBIT: -207000000.00
XRAY income_statement (quarterly, 2025-09-30) — EBITDA: -115000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -3000000.00
XRAY cash_flow (quarterly, 2025-09-30) — End Cash Position: 363000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -36000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Finished Goods: 402000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 40000000.00
XRAY income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 13000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -672000000.00
XRAY income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 358000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Goodwill: 1270000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 2335000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 666000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Gross PPE: 972000000.00
XRAY income_statement (quarterly, 2025-09-30) — Gross Profit: 441000000.00
XRAY income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 262000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 47000000.00
XRAY income_statement (quarterly, 2025-09-30) — Interest Expense: 23000000.00
XRAY income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 23000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Inventory: 686000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Invested Capital: 3873000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -36000000.00
XRAY cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 1000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 85000000.00
XRAY balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 2017000000.00